RESUMO
BACKGROUND: Post-placement menstrual bleeding pattern changes with intrauterine contraceptives (IUCs), including levonorgestrel-releasing intrauterine systems (LNG-IUS), can be a reason for avoidance or early discontinuation. Prostaglandins play an important role in menstrual bleeding and pain. The key drivers of prostaglandin synthesis are cyclooxygenase (COX) enzymes, which are inhibited by non-steroidal anti-inflammatory drugs. In this study, we report the findings from pharmacokinetic (PK) analyses undertaken with an LNG-IUS (LNG-IUS 8) modified with an additional reservoir containing indomethacin (IND). METHODS: The IND/LNG-IUS 8 is a proof-of-concept device studied in a phase II proof-of-concept/dose-finding study. IND/LNG-IUS 8 contains the same LNG content as the unmodified LNG-IUS 8 (13.5 mg) but was prepared with three different IND doses (low, 6.5 mg; middle, 12.5 mg; and high, 15.4 mg), resulting in different daily release rates. Overall, 174 healthy, premenopausal women were randomized to one of the four treatment arms (low-, middle-, high-dose IND/LNG-IUS 8 or LNG-IUS 8). Initial and residual IND and LNG content were collected and the amount of IND and LNG released in vivo over the period of use was calculated. A subset of 62 participants underwent dense blood sampling for PK analysis. Concentrations of IND and LNG in plasma were determined by validated liquid chromatography-tandem mass spectrometry methods and plotted over time. Descriptive statistics were calculated for plasma drug concentrations and PK parameters. RESULTS: High-dose IND/LNG-IUS 8 initially released much higher levels of IND than expected based on in vitro release data, followed by a steep decline, with the reservoir emptied by 4.5 months. Middle- and low-dose IND/LNG-IUS 8 demonstrated steady sustained release of IND over time, emptying after 7.4 and 8.4 months, respectively. Peak plasma concentrations of IND for low- and middle-dose IND/LNG-IUS 8 remained below the 20% maximal inhibitory concentration (IC20) values for COX enzymes. The average daily IND release rate in vivo was 49 µg/day for low-dose and 112 µg/day for middle-dose IND/LNG-IUS 8. The IND release rate profile and IND plasma concentrations in vitro both decreased steadily over time with low- and middle-dose IND/LNG-IUS 8. The LNG release rate profile was comparable for all IND/LNG-IUS 8 dose groups and LNG-IUS 8. CONCLUSION: This PK study demonstrates that two different drugs can be released at different rates from an IUS designed with two drug reservoirs. Inclusion of IND does not impact the LNG PK profile. Low- and middle-dose IND/LNG-IUS 8 were associated with a systemic IND exposure that should preclude the occurrence of adverse events typically observed after oral IND dosing. STUDY REGISTRATION: ClinicalTrials.gov identifier number: NCT03562624.
Assuntos
Dispositivos Intrauterinos Medicados , Levanogestrel , Feminino , Humanos , Levanogestrel/efeitos adversos , Indometacina , Dispositivos Intrauterinos Medicados/efeitos adversos , Nível de SaúdeRESUMO
BACKGROUND: Long-acting reversible contraceptives, including hormonal levonorgestrel-releasing intrauterine systems, are the most effective methods of reversible contraception. However, unfavorable bleeding, particularly during the first months of use, is one of the most important reasons for discontinuation or avoidance. Minimizing this as early as possible would be highly beneficial. Nonsteroidal anti-inflammatory drugs inhibiting prostaglandin synthesis are known to reduce bleeding and pain at time of menses. A levonorgestrel-releasing intrauterine system has been developed with an additional reservoir containing indomethacin, designed to be released during the initial postplacement period. OBJECTIVE: This proof-of-concept study aimed to establish whether the addition of indomethacin to the currently available levonorgestrel-releasing intrauterine system (average in vivo levonorgestrel release rate of 8 µg/24 h during the first year of use) reduces the number of bleeding and spotting days during the first 90 days of use compared with the unmodified system. The dose-finding analysis included 3 doses of indomethacin-low (6.5 mg), middle (12.5 mg), and high (15.4 mg)-to determine the ideal dose of indomethacin to reduce bleeding and spotting days with minimal side-effects. STUDY DESIGN: This was a multicenter, single-blinded, randomized, controlled phase II trial conducted between June 2018 and June 2019 at 6 centers in Europe. Three indomethacin dose-ranging treatment groups (low-, middle-, and high-dose indomethacin/levonorgestrel-releasing intrauterine system) were compared with the unmodified levonorgestrel-releasing intrauterine system group, with participants randomized in a 1:1:1:1 ratio. The primary outcome was the number of uterine bleeding and spotting days over a 90-day reference (treatment) period. Secondary outcomes were the number of women showing endometrial histology expected for intrauterine levonorgestrel application and the frequency of treatment-emergent adverse events. Point estimates and 2-sided 90% credible intervals were calculated for mean and median differences between treatment groups and the levonorgestrel-releasing intrauterine system without indomethacin. Point and interval estimates were determined using a Bayesian analysis. RESULTS: A total of 174 healthy, premenopausal women, aged 18 to 45 years, were randomized, with 160 women eligible for the per-protocol analysis set. Fewer bleeding and spotting days were observed in the 90-day reference period for the 3 indomethacin/levonorgestrel-releasing intrauterine system dose groups than for the levonorgestrel-releasing intrauterine system without indomethacin group. The largest reduction in bleeding and spotting days was achieved with low-dose indomethacin/levonorgestrel-releasing intrauterine system, which demonstrated a point estimate difference of -32% (90% credible interval, -45% to -19%) compared with levonorgestrel-releasing intrauterine system without indomethacin. Differences for high- and middle-dose indomethacin/levonorgestrel-releasing intrauterine system groups relative to levonorgestrel-releasing intrauterine system without indomethacin were -19% and -16%, respectively. Overall, 97 women (58.1%) experienced a treatment-emergent adverse event considered related to the study drug, with similar incidence across all treatment groups including the unmodified levonorgestrel-releasing intrauterine system. These were all mild or moderate in intensity, with 6 leading to discontinuation. Endometrial biopsy findings were consistent with effects expected for the levonorgestrel-releasing intrauterine system. CONCLUSION: All 3 doses of indomethacin substantially reduced the number of bleeding and spotting days in the first 90 days after placement of the levonorgestrel-releasing intrauterine system, thus providing proof of concept. Adding indomethacin to the levonorgestrel-releasing intrauterine system can reduce the number of bleeding and spotting days in the initial 90 days postplacement, without affecting the safety profile, and potentially improving patient acceptability and satisfaction.
Assuntos
Anticoncepcionais Femininos , Dispositivos Intrauterinos Medicados , Metrorragia , Feminino , Humanos , Levanogestrel/uso terapêutico , Indometacina , Teorema de Bayes , Dispositivos Intrauterinos Medicados/efeitos adversos , Anticoncepcionais Femininos/efeitos adversos , Metrorragia/etiologiaRESUMO
PURPOSE: To evaluate if erythromycin compromises liver-specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) -mediated hepatocytic uptake. MATERIALS AND METHODS: The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre- and 20 min postcontrast two-dimensional gradient-recalled-echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV). RESULTS: Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 µmol/L (CV 20.4%) after erythromycin infusion and 129.6 µmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant). CONCLUSION: Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging.
Assuntos
Eritromicina/administração & dosagem , Gadolínio DTPA/administração & dosagem , Fígado/anatomia & histologia , Imageamento por Ressonância Magnética , Transportadores de Ânions Orgânicos/antagonistas & inibidores , Adulto , Meios de Contraste , Interações Medicamentosas , Feminino , Humanos , Fígado/efeitos dos fármacos , Masculino , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
This is a report of a workshop held on the establishment of human research tissue banking which was held in Levi, Finland 21-24 March 2002. There were 21 participants from 7 European countries. This meeting was attended by representatives from academia, research tissue banks and from the Biotech and Pharmaceutical Industries. The principal aim of the workshop was to find a way to progress the recommendations from ECVAM workshop 44 (ATLA 29, 125-134, 2001) and ECVAM workshop 32 (ATLA 26, 763-777, 1998). The workshop represented the first unofficial meeting of the European Network of Research Tissue Banks (ENRTB) steering group. It is expected that in the period preceding the next workshop the ENRTB steering group will co-ordinate the ethical, legislative and organisational aspects of research tissue banking. Key issues dealt with by the Levi workshop included the practical aspects of sharing expertise and experiences across the different European members. Such collaboration between research tissue banks and end users of such material seeks to ultimately enable shared access to human tissue for medical and pharmaco-toxicological research while maintaining strict adherence to differences in legal and ethical aspects related to the use of human tissue in individual countries.
RESUMO
The prototype of a microprocessor controlled oxygen uptake monitor oxyconsumeter developed by Draegerwerk AG, Luebeck, FRG, has been tested. The measuring accuracy of this device was assessed with laboratory bench experiments utilizing both the nitrogen dilution technique and the hydrogen combustion technique to simulate oxygen uptake (VO2). The correlation coefficient between the simulated and the measured VO2 values was 0.9989 (p less than 0.05, n = 115). The average relative error of the VO2 values was -3.32% +/- 3.88% when breathing 21 vol% oxygen and -5.58% +/- 4.53% for 70 vol% oxygen (percent of reading). This was within the range given by the manufacturer (+/- 5% for 21 vol% to less than 40 vol%, +/- 10% for 40 vol% to less than 70 vol%) with few exceptions. Furthermore the oxyconsumeter was used in clinical experiments to determine oxygen uptake during general anaesthesia. Oxygen uptake was monitored using a non-rebreathing system with an externally triggered expiratory valve. The difference between preanaesthetic reference values and values determined during anaesthesia averaged -24.8 +/- 20.1 ml/min/m2 oxygen. This average relative change of -16.0 +/- 11.5% was statistically significant in 11 of 15 cases (p less than 0.05).
Assuntos
Microcomputadores , Monitorização Fisiológica/instrumentação , Consumo de Oxigênio , Adulto , Idoso , Anestesia Geral , Feminino , Humanos , Unidades de Terapia Intensiva , Cuidados Intraoperatórios/instrumentação , Pessoa de Meia-IdadeRESUMO
Eight different breathing gas humidifiers were tested by humidity measurements using two independent methods under simulated clinical conditions. The comparison considering the influence of tidal volume and inspiratory/expiratory ratios revealed great differences between the individual devices depending on the kind of humidification and functional principles. Only four of the humidifiers tested: Ultrasonic Nebulizer NB 108, Hydrotrop 200, Bennett Cascade and Nicholas Humidifier, gave a constant performance of more than 30.75 g H2O/m3 absolute humidity or 70% relative humidity, related to 37 degrees C. However, humidification and heating of the inspired gas could be ensured only by the last three devices. The humidifiers Bird 500 cm3 Micronebulizer, Ultrasonic Nebulizer NB 100 and Draeger Compressor 660, were strongly dependent on the respiration parameters and exceeded the required minimum of 70% relative humidity only under certain conditions. The Engstroem ER-200 Vaporizer had a low performance and was not suitable as a breathing gas humidifier for longterm ventilation.
Assuntos
Umidade , Respiração , Terapia Respiratória/instrumentação , HumanosRESUMO
Until now the only successful growth of postembryonic skin in explant cultures has been with human skin. We describe the successful cultivation of postembryonic mouse skin explant culture in this report. We believe that any adult skin can be grown in explant culture.